- Home
- LPTX vs MDBH Comparison
LPTX vs MDBH Comparison
Compare LPTX & MDBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- MDBH
- Stock Information
- Founded
- LPTX 2011
- MDBH 1997
- Country
- LPTX United States
- MDBH United States
- Employees
- LPTX N/A
- MDBH N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- MDBH
- Sector
- LPTX Health Care
- MDBH
- Exchange
- LPTX Nasdaq
- MDBH Nasdaq
- Market Cap
- LPTX 35.4M
- MDBH 38.2M
- IPO Year
- LPTX N/A
- MDBH 2023
- Fundamental
- Price
- LPTX $0.42
- MDBH $3.70
- Analyst Decision
- LPTX Hold
- MDBH
- Analyst Count
- LPTX 1
- MDBH 0
- Target Price
- LPTX N/A
- MDBH N/A
- AVG Volume (30 Days)
- LPTX 7.1M
- MDBH 23.4K
- Earning Date
- LPTX 11-13-2025
- MDBH 11-14-2025
- Dividend Yield
- LPTX N/A
- MDBH N/A
- EPS Growth
- LPTX N/A
- MDBH N/A
- EPS
- LPTX N/A
- MDBH 0.56
- Revenue
- LPTX N/A
- MDBH N/A
- Revenue This Year
- LPTX N/A
- MDBH N/A
- Revenue Next Year
- LPTX N/A
- MDBH N/A
- P/E Ratio
- LPTX N/A
- MDBH $6.75
- Revenue Growth
- LPTX N/A
- MDBH N/A
- 52 Week Low
- LPTX $0.22
- MDBH $3.16
- 52 Week High
- LPTX $4.24
- MDBH $9.42
- Technical
- Relative Strength Index (RSI)
- LPTX 42.80
- MDBH 46.18
- Support Level
- LPTX $0.43
- MDBH $3.80
- Resistance Level
- LPTX $0.56
- MDBH $4.80
- Average True Range (ATR)
- LPTX 0.06
- MDBH 0.38
- MACD
- LPTX -0.02
- MDBH -0.03
- Stochastic Oscillator
- LPTX 0.04
- MDBH 16.03
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About MDBH MDB Capital Holdings LLC common
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The Company operates in two reportable segments: a broker dealer & intellectual property service, and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.